WMS 2025 Sysnav Healthcare

Sysnav Healthcare at WMS 2025

Sysnav Healthcare was delighted to participate in the 30th Annual International Congress of the World Muscle Society, in Vienna, Austria, from October 7 to 11, 2025.

Our team presented four posters demonstrating how digital biomarkers and wearable technology can objectively track disease progression across a range of neuromuscular disorders:

  • DMD: two posters in collaboration with Prof. Laurent Servais’ team from Oxford University and CHR Citadelle in Liège, presenting longitudinal results in patients above and below 4 years old. Download them here and here.
  • FSHD: a poster in collaboration with Prof. John Vissing’s team from Rigshospitalet, on the analytical validation of Syde®’s measurements of upper- and lower-limb movements. Download it here.
  • CMT and DM1: a poster in collaboration with Prof. Laurent Servais’ team, on the feasibility of using a wearable digital health technology sensor to assess ambulation in this patient population. Download it here. 

We are grateful to the World Muscle Society for bringing together the global neuromuscular research community and facilitating this event.

Witnessing the latest advances in research and emerging therapies has energized the Sysnav team, inspiring us to advance the use of digital biomarkers in neuromuscular research.

More To Explore

Sysnav Healthcare at ICNMD 2026
Events

Sysnav Healthcare at ICNMD 2026

How do you assess a patient too young to follow instructions? That’s the challenge our Program Director, Damien Eggenspieler, tackled on the ground at ICNMD

Sysnav Healthcare at EAN
Events

Sysnav Healthcare at EAN 2026

Can a single wearable platform derive meaningful clinical conclusions across 10+ neurological diseases? The evidence says yes.We’re presenting three new posters at EAN 2025, each

Sysnav Healthcare is participating in ENCALS 2026
Events

Sysnav Healthcare at ENCALS 2026

As the development of innovative therapies for ALS accelerates around the world, the need for objective and clinically meaningful measures of disease progression has never